KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Debt: 2009-2016

Historic Non-Current Debt for Vertex Pharmaceuticals (VRTX) over the last 1 years, with Jun 2016 value amounting to $74.9 million.

  • Vertex Pharmaceuticals' Non-Current Debt fell 70.26% to $74.9 million in Q2 2016 from the same period last year, while for Jun 2016 it was $74.9 million, marking a year-over-year decrease of 70.26%. This contributed to the annual value of $223.9 million for FY2015, which is 20.21% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Non-Current Debt stood at $74.9 million for Q2 2016, which was down 49.91% from $149.6 million recorded in Q1 2016.
  • In the past 5 years, Vertex Pharmaceuticals' Non-Current Debt registered a high of $294.8 million during Q3 2015, and its lowest value of $74.9 million during Q2 2016.
  • Its 3-year average for Non-Current Debt is $229.6 million, with a median of $259.1 million in 2015.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Non-Current Debt rose by 0.03% in 2015, and later slumped by 70.26% in 2016.
  • Vertex Pharmaceuticals' Non-Current Debt (Quarterly) stood at $280.6 million in 2014, then declined by 20.21% to $223.9 million in 2015, then crashed by 70.26% to $74.9 million in 2016.
  • Its Non-Current Debt stands at $74.9 million for Q2 2016, versus $149.6 million for Q1 2016 and $223.9 million for Q4 2015.